Please use this identifier to cite or link to this item:
|Title:||Tri-substituted imidazole analogues of SB203580 as inducers for cardiomyogenesis of human embryonic stem cells|
Human embryonic stem cells
|Citation:||Low, J.-L., Jürjens, G., Seayad, J., Seow, J., Ting, S., Laco, F., Reuveny, S., Oh, S., Chai, C.L.L. (2013-06-01). Tri-substituted imidazole analogues of SB203580 as inducers for cardiomyogenesis of human embryonic stem cells. Bioorganic and Medicinal Chemistry Letters 23 (11) : 3300-3303. ScholarBank@NUS Repository. https://doi.org/10.1016/j.bmcl.2013.03.103|
|Abstract:||The p38α mitogen-activated protein kinase (MAPK) inhibitor SB203580 had been reported to enhance the cardiomyogenesis of human embryonic stem cells (hESCs). To investigate if tri-substituted imidazole analogues of SB203580 are equally effective inducers for cardiomyogenesis of hESCs, and if there is a correlation between p38α MAPK inhibition and cardiomyogenesis, we designed and synthesized a series of novel tri-substituted imidazoles with a range of p38α MAPK inhibitory activities. Our studies demonstrated that suitably designed analogues of SB203580 can also be inducers of cardiomyogenesis in hESCs and that cell growth is affected by changes in the imidazole structures. © 2013 Elsevier Ltd. All rights reserved.|
|Source Title:||Bioorganic and Medicinal Chemistry Letters|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jun 23, 2018
WEB OF SCIENCETM
checked on May 29, 2018
checked on Apr 20, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.